ProPhase Labs, Inc. (PRPH) financial statements (2022 and earlier)

Company profile

Business Address 711 STEWART AVE, SUITE 200
NEW YORK, NY 11530
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17,2638,4551,3608,24121,938441
Cash and cash equivalents8,4086,8164341,5543,173441
Short-term investments8,8551,6399266,68718,765 
Receivables37,7083,1552,0102,9681,9455,770
Inventory, net of allowances, customer advances and progress billings4,6003,0391,4591,9031,5312,736
Inventory4,6003,0391,4591,9031,5312,736
Prepaid expense    143263
Assets held-for-sale, not part of disposal group    22 
Other undisclosed current assets1,7461,2385,1165,1262,838417
Total current assets:61,31715,8879,94518,23828,4179,627
Noncurrent Assets
Operating lease, right-of-use asset4,4024,731 
Property, plant and equipment5,9473,5782,3292,4992,7423,175
Intangible assets, net (including goodwill)16,5612,135    
Goodwill5,709901    
Intangible assets, net (excluding goodwill)10,8521,234    
Prepaid expense4602,084    
Other noncurrent assets608240    
Other undisclosed noncurrent assets 2,750  2,500 
Total noncurrent assets:27,97815,5182,3292,4995,2423,175
TOTAL ASSETS:89,29531,40512,27420,73733,65912,802
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,0263,7714323,3667624,961
Accounts payable7,0263,7714324375622,156
Accrued liabilities    2002,805
Interest and dividends payable   2,929  
Deferred revenue2,034  
Debt     1,490
Other liabilities3,8071,7314097661,050389
Other undisclosed current liabilities2,65779292101  
Total current liabilities:15,5246,2949334,2331,8126,840
Noncurrent Liabilities
Long-term debt and lease obligation14,23814,393    
Long-term debt, excluding current maturities10,0409,991    
Operating lease, liability4,1984,402 
Liabilities, other than long-term debt905162110   
Deferred revenue905162110
Total noncurrent liabilities:15,14314,555110   
Total liabilities:30,66720,8491,0434,2331,8126,840
Stockholders' equity
Stockholders' equity attributable to parent58,62810,55611,23116,50431,8475,962
Common stock161414141413
Treasury stock, value(48,407)(47,490)(47,490)(47,490)(47,025)(30,742)
Additional paid in capital104,55261,67460,21559,47158,03456,378
Accumulated other comprehensive loss(175)(11)(2)(24)(78) 
Retained earnings (accumulated deficit)2,642(3,631)(1,506)4,53320,902(19,687)
Total stockholders' equity:58,62810,55611,23116,50431,8475,962
TOTAL LIABILITIES AND EQUITY:89,29531,40512,27420,73733,65912,802

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues79,04214,5149,87613,1269,86721,014
Revenue, net9,86721,014
Cost of revenue
(Cost of Goods and Services Sold)
(37,054)(9,908)(7,261)(8,345)(7,919)(10,948)
Gross profit:41,9884,6062,6154,7811,94810,066
Operating expenses(32,187)(8,591)(5,854)(6,415)(5,938)(12,722)
Other operating income, net    152 
Other undisclosed operating income 1,892    
Operating income (loss):9,801(2,093)(3,239)(1,634)(3,838)(2,656)
Nonoperating income64262133 54 
Investment income, nonoperating64262133   
Other nonoperating income    54 
Interest and debt expense(1,148)(295)  (54)(213)
Income (loss) from continuing operations before equity method investments, income taxes:9,295(2,326)(3,106)(1,634)(3,838)(2,869)
Other undisclosed income (loss) from continuing operations before income taxes(3,990)  1671751
Income (loss) from continuing operations before income taxes:5,305(2,326)(3,106)(1,467)(3,663)(2,868)
Income tax expense (benefit)968  (103)1,421 
Income (loss) from continuing operations:6,273(2,326)(3,106)(1,570)(2,242)(2,868)
Income (loss) from discontinued operations 201(40)(170)42,831 
Net income (loss) available to common stockholders, basic:6,273(2,125)(3,146)(1,740)40,589(2,868)
Other undisclosed net income available to common stockholders, diluted1,000     
Net income (loss) available to common stockholders, diluted:7,273(2,125)(3,146)(1,740)40,589(2,868)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):6,273(2,125)(3,146)(1,740)40,589(2,868)
Comprehensive income (loss):6,273(2,125)(3,146)(1,740)40,589(2,868)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(164)(9)2254(78) 
Comprehensive income (loss), net of tax, attributable to parent:6,109(2,134)(3,124)(1,686)40,511(2,868)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: